Ποια είναι η τιμή για BioVaxys Technology Corp. (BIOV)

Η τιμή για BioVaxys Technology Corp. (BIOV) είναι $0.05137558

Ποια είναι η κεφαλαιοποίηση αγοράς για BioVaxys Technology Corp. (BIOV)

Η κεφαλαιοποίηση αγοράς για BioVaxys Technology Corp. (BIOV) είναι $1.50M

BioVaxys Technology Corp. (BIOV) Τιμή και Κεφαλαιοποίηση Αγοράς

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

Η τιμή για BIOV	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$187,008 $1.50M	NVDA	$5.452T	+364,001,979.13%
$154,015 $1.50M	AAPL	$4.490T	+299,782,792.18%
$142,778 $1.50M	GOOG	$4.162T	+277,909,211.65%
$126,105 $1.50M	MSFT	$3.676T	+245,456,385.18%
$97,178.10 $1.50M	AMZN	$2.833T	+189,152,215.58%

Η τιμή για BIOV

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$187,008 $1.50M